ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 115 for:    Recruiting, Not yet recruiting, Available Studies | "Diabetes, Gestational"

Supporting American Indian/Alaska Native Mothers and Daughters in Reducing Gestational Diabetes Risk

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02723266
Recruitment Status : Recruiting
First Posted : March 30, 2016
Last Update Posted : April 5, 2018
Sponsor:
Collaborators:
University of Colorado, Denver
University of Oklahoma
Sundance Research Institute
St. Regis Mohawk
Indian Health Care Resource Center of Tulsa
Children's Hospital of Philadelphia
Brigham and Women's Hospital
Information provided by (Responsible Party):
Denise Charron-Prochownik, University of Pittsburgh

Brief Summary:
The purpose of this study is to modify an existing Reproductive Health intervention for adolescents with diabetes for Gestational Diabetes and make it culturally appropriate American Indian/Alaska Native adolescents. The intervention will then be evaluated for effectiveness in AI/AN female teens at risk for GDM.

Condition or disease Intervention/treatment Phase
Gestational Diabetes Mellitus Behavioral: STOPPING-GDM Not Applicable

Detailed Description:
Gestational diabetes mellitus (GDM) has escalated to epidemic proportion and can cause maternal and child complications. GDM is a significant maternal risk factor for subsequent development of type 2 diabetes (T2D) and places the fetus at increased risk for congenital morbidity/mortality and for future onset of diabetes. American Indian and Alaska Native (AI/AN) women are twice as likely to develop GDM and T2D; mostly due to healthcare disparities (e.g., limited access to resources, lack of culturally relevant programs). The need for an inexpensive accessible GDM intervention in this population is compelling. The intervention should be delivered during adolescence and prior to sexual debut. Preconception counseling (PC) prevents unplanned pregnancies and significantly reduces risks of complications. If GDM in a previous pregnancy is an indicator of high risk in subsequent pregnancies, then preventing GDM in a first pregnancy is imperative. For a significant and innovative shift in paradigm, the Investigators propose a primary prevention PC intervention for AI/AN adolescent females at risk for GDM to enhance healthy lifestyle behaviors and family planning vigilance prior to this first pregnancy. The Investigators will target girls starting at the age of 12 to coincide with both the "Coming-of-Age" rituals for AI/AN girls during which many receive womanly advice from elder female family members, and the American Diabetes Association recommendation that PC in all females should start at puberty. This new directive will require support from the teens' mothers (or their female caregiver) and well-informed community health care professionals (HCP). Our objective is to adapt our current PC intervention (validated for teens with diabetes) using a sequential mixed-method design with a multi-tribal AI/AN community-based participatory research (CBPR) approach (e.g., Navajo, Cherokee, 40 Oklahoma tribes; 8 project members are AI/AN) by first using focus groups of teens, mothers, HCP, and Tribal leaders; and then testing this culturally appropriate PC theory-based intervention named Stopping GDM in AI/AN adolescent females 12 to <20yrs at risk for GDM (e.g., pre-diabetes or BMI> 85%). Teens and their mothers will receive the Stopping GDM to raise their awareness of the risks of GDM and benefits of healthy lifestyle to reduce these risks. By also providing mothers with PC knowledge and skills they can naturally weave cultural/social influences into their communications with their daughters. The multi-level intervention will be directed at the individual, familial and institutional levels simultaneously. AI/AN community-researcher partnerships have been established. A randomized controlled trial with a 15mos follow-up will test the effects of receiving online Stopping GDM on mother-daughter (M-D) cognitive/psychosocial and behavioral outcomes, and daughter family planning vigilance. The final online Stopping GDM program will be provided at no cost to the Indian Health Service (IHS) for dissemination to all their sites. HCPs at each clinical facility will be given free access to a continuing education program for PC training. This proposal provides a unique opportunity for a broad dissemination to significantly impact all IHS AI/AN female teens at risk for GDM, and help to prevent them and their future children from developing T2D.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Supporting American Indian/Alaska Native Mothers and Daughters in Reducing Gestational Diabetes Risk
Actual Study Start Date : March 16, 2018
Estimated Primary Completion Date : November 30, 2019
Estimated Study Completion Date : March 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention
Treatment receives the STOPPING-GDM intervention. Control does not receive the intervention.
Behavioral: STOPPING-GDM
Educational counseling and skills building Intervention

No Intervention: Control
Control does not receive the intervention.



Primary Outcome Measures :
  1. Reproductive Health Behaviors [ Time Frame: 15 months ]
    Family-Planning Vigilance Behavior are defined as using effective family planning/abstinence, seeking PC, and initiating discussion with health care professionals . "Effective family planning behaviors" is a weight summary of the teen's most frequently used contraception. Weights will be derived using the annual failure rates for methods of contraception reported in Trussell's algorithm. Rates are transformed into probabilities of failure (0 to 1), 0 = no failure. Overall effectiveness of contraception is computed as 1-Pr [Failure]. Combination methods (> 2 jointly) is the product of the failure probability of the individual methods used jointly. For multiple methods used singly, the overall probability of failure will be computed as the average of the failure probabilities. Subjects who were never sexually active will be given a failure probability of zero

  2. Beliefs and Attitudes [ Time Frame: 15 months ]
    Beliefs/attitudes Reproductive Health and Diabetes Questionnaire (EHBM scale) Based on the EHBM,[53, 76, 82] perceived susceptibility (9 items) and perceived severity (7), perceived benefits (12) of and barriers (15), and self-efficacy (18) (confidence to use FPV); Likert-type (1=strongly disagree to 7=strongly agree).[76] Each construct has a composite score; higher= stronger attitudes. (alphas: susceptibility = .74; severity = .94; benefit = .88; barriers = .97; self-efficacy = .96

  3. Knowledge/Decision-Making [ Time Frame: 15 Months ]
    Knowledge/decision-making Reproductive-health Awareness for Teens with DM Quest (Knowledge scale) Multiple choice, based on 100% correctness, subscales: diabetes and pregnancy (28 items); contraception (5); sexuality (7); puberty (3); PC (25); and general family planning (8) (Cronbach alpha .71; test-retest reliability r= 0.76). Split-half differentiates pre- from post-test

  4. Social Support [ Time Frame: 15 months ]
    Social Support Reproductive Health and Diabetes Q. (Social Support scale) Social support is the process by which help is obtained from the social network (e.g., mothers/ female guardian) to meet one's needs. Support measure for mothers is the perceived actual support (emotional, appraisal, informational, and instrumental)[54] they provided to their daughters for lifestyle management and family planning vigilance. Daughters' measure is perceived available support from their mother for the same behaviors. Summation score of 9 items with responses, "a lot of help" =7 to "no help at all" =1. Higher scores = greater support. Alpha = .92

  5. Initiating Discussion [ Time Frame: 15 months ]
    Initiating Discussions with M-D Initiating Discussion M-D Scale Teens and mothers respond to 4 yes/no items of actual discussions they have had regarding GDM and reproductive health issues (pregnancy, sexuality, birth control and PC

  6. Lifestyle Management [ Time Frame: 15 months ]
    Lifestyle Self-Management Lifestyle Self-Management Scale (DM Care Profile) Daughter's adherence is a 3-item scale (1= "not very well done" to 7= "very well done") based on diabetes-prevention self-care management (diet, physical activity, clinic visits).[84] Cronbach's alpha from our studies is .75. Culturally-relevant items will be added during Phase 1


Secondary Outcome Measures :
  1. BMI [ Time Frame: 15 months ]
    Body Mass Index (BMI) BMI percentile a standard parameter for obesity will be the measured weight (kilograms) divided by measured height using a stadiometer (meters) squared. Change in BMI will be analyzed. Percentiles will be specific to sex and month of age using algorithms by the Center for Disease Control. BMI z scores will also be calculated. Identical scales and stadiometers, provided by the study, will be calibrated according to the manufacturer. Protocols/ categories from the SEARCH study will be used.

  2. Hemoglobin A1C values to evaluate Glycemic Control [ Time Frame: 15 months ]
    Glycosylated Hemoglobin (A1C) A1C is a standard index of long-term glycemic control, reflecting 3-month average blood glucose levels. Clinic A1C values will be recorded from the subjects' medical records, and entered into the online database. Each site uses the same standardized method for obtaining A1C samples. Blood will be collected from a finger stick and analyzed immediately. Each site will use the same manufacturer's calibration techniques . The investigators will evaluate changes in glycemic control per the categories in the American Diabetes Association guidelines. A Glycosylated Hemoglobin (A1C) > 6.5% is an exclusion criteria.

  3. Number of subjects reporting an unplanned pregnancy [ Time Frame: 15 months ]
    Self Report of Unplanned Pregnancy (no or yes) since last visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Daughter(index subject)

  • females between the ages of 12 to <20 years
  • at risk for GDM (such as having metabolic syndrome, pre-diabetes, or BMI > 85%; and an A1C < 6.5%)
  • fluent in English.

Inclusion criteria: Mother (or significant female caregiver, e.g., grandmother, aunt, adult sister, stepmother) of daughters at risk for GDM

  • natural, adoptive, or step, living with their daughters
  • fluent in English

Exclusion Criteria: Daughters:

  • A1C > 6.5%, [20, 26] abnormal Glucose Tolerance Test (GTT),
  • signs and symptoms of diabetes,
  • a history of another chronic illness or mental retardation,
  • pregnant at the time of recruitment.

Exclusion Criteria Mothers:

  • foster mother of an adolescent girl because she may not be a consistent caregiver.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02723266


Contacts
Contact: Denise Charron-Prochownik, PhD 412-624-6953 dcpro@pitt.edu
Contact: Andrea Fischl, PhD 412-624-5054 afr4@pitt.edu

Locations
United States, Oklahoma
Indian Health Resource Center of Tulsa Recruiting
Tulsa, Oklahoma, United States, 73114
Contact: Nancy O'Banion, MS    918-382-2220    nobanion@IHCRC.org   
Contact: Sharnella Goudeau, RN    918-619-4304    sharnella-gourdeau@ouhsc.edu   
Sponsors and Collaborators
University of Pittsburgh
University of Colorado, Denver
University of Oklahoma
Sundance Research Institute
St. Regis Mohawk
Indian Health Care Resource Center of Tulsa
Children's Hospital of Philadelphia
Brigham and Women's Hospital
Investigators
Study Director: Nancy O'Bannion, MS Indian Health Care Resource Center of Tulsa
Study Director: Jeff Powell, MD University of Colorado (Shiprock-subcontract )

Responsible Party: Denise Charron-Prochownik, Principal Investigator, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02723266     History of Changes
Other Study ID Numbers: 1R01NR014831-01A1 ( U.S. NIH Grant/Contract )
First Posted: March 30, 2016    Key Record Dates
Last Update Posted: April 5, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: It is our intention to make all data generated from this proposal freely available. The primary mechanism of data dissemination will be through submission of abstracts to regional, national, and international meetings and the submission of manuscripts. The principal investigator will serve as liaison with other investigators in the sharing of additional materials if necessary.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Denise Charron-Prochownik, University of Pittsburgh:
American Indian, Alaska Native Adolescents
Preconception Counseling
Reproductive Health
Gestational Diabetes Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes, Gestational
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications
Tin Fluorides
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs